Hypertension Clinical Trial
— ADAMPAOfficial title:
Impact of Self-monitoring of Blood Pressure and Self-titration of Antihypertensive Medication in the Control of Hypertension and Adherence to Treatment. A Pragmatic, Randomized, Controlled Clinical Trial (ADAMPA Study).
Verified date | August 2021 |
Source | Fundación para la Investigación del Hospital Clínico de Valencia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The ADAMPA study is a pragmatic randomized clinical trial which aims to evaluate the effectiveness of an intervention based on self-monitoring and self-titration of medication in poorly controlled hypertensive patients 40 years and older. The total duration of the study is 3 years, with 6 months of enrolment and 1 year of follow-up to measure the primary endpoint (Difference in mean systolic blood pressure, in mmHg, between the intervention and control groups).
Status | Completed |
Enrollment | 366 |
Est. completion date | August 25, 2020 |
Est. primary completion date | July 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - 40 years or older - Diagnosis of hypertension of any origin - Systolic blood pressure (SBP) > 145 or diastolic blood pressure (DBP) > 90 mm Hg at baseline - Voluntarily participation in the study and having signed the corresponding informed consent. Exclusion Criteria: - Inability to understand and/or perform self-adjustment of the medication, including dementia or significant cognitive impairment (at the discretion of the investigator performing the recruitment). - History of orthostatic hypotension (fall> 20 mm Hg in SBP after adopting the orthostatic position). - SBP> 200 or DBP> 100 mm Hg on the baseline examination - Being on treatment with more than 4 antihypertensive drugs - Participation in another study on high blood pressure or in a clinical trial - Presence of tremor or neurological disease that makes it difficult to perform BP self-measurement. - Presence of arrhythmia - Presence of terminal illness - Chronic disability impeding to leave home - History of acute cardiovascular event in the last 3 months - Hypertension managed directly by specialist physicians outside the primary care setting. - Spouse selected for the study - Non-resident or transient patients - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Spain | Departamento de Salud Valencia Clínico Malvarrosa | Valencia |
Lead Sponsor | Collaborator |
---|---|
Fundación para la Investigación del Hospital Clínico de Valencia | Carlos III Health Institute, Spanish Clinical Research Network - SCReN |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in lifestyle | Changes in lifestyle (smoking, exercise, body weight) at 6, 12, and 24 months compared to these characteristics at baseline. | 6,12,24 months | |
Other | Adverse events | We will assess if any of the following adverse events are present during the follow-up: angor, myocardial infarction, stroke, hypotensive crisis and death. | 12 months | |
Other | Health services utilization | Health services utilization during follow-up (6, 12 and 24 months), will include: visits to primary care nurse and physician, related to high blood pressure (HBP) (including telephone and home), emergency visits to hospital, hospital admissions, hospitalization days per admission and principal diagnosis. | 6,12 and 24 months | |
Other | Incremental cost per quality-adjusted life year gained | Incremental cost per quality-adjusted life year gained in the intervention group as compared to the control group. | 12 months | |
Other | Satisfaction with the intervention | Qualitative evaluation of the intervention by patients and research physicians, through a satisfaction scale. | 12 months | |
Primary | Mean systolic blood pressure (SBP). | Difference in mean systolic blood pressure, in mmHg. At 12 months of follow-up between the intervention and control groups, determined at physicians' practice with a validated automatic electronic sphygmomanometer | 12 months from start of intervention | |
Secondary | Mean systolic blood pressure at 6 and 24 months | Difference in mean systolic blood pressure, in mmHg at 6 and 24 months of follow-up between intervention and control groups determined at physicians' practice with a validated automatic electronic sphygmomanometer | 6 and 24 months | |
Secondary | Mean diastolic blood pressure (DBP) at 6 and 24 months | Difference in mean diastolic blood pressure, in mmHg at 6 and 24 months of follow-up between intervention and control groups determined at physicians' practice with a validated automatic electronic sphygmomanometer | 6 and 24 months | |
Secondary | Percentage of patients with normal SBP and DBP | Percentage of patients with SBP<140 mmHg and DBP <90 mmHg at 6, 12 y 24 months of follow-up | 6,12, 24 months | |
Secondary | EuroQoL-5D score | Score in the EuroQoL-5D at 6, 12 and 24 months of follow-up | 6,12,24 months | |
Secondary | Medication adherence | Proportion of days covered (PDC) will be measured, dividing the number of days with dispensed medication by the number of days of follow-up. Patients with PDC = 80 will be considered adherent. In case of polypharmacy, patients with PDC = 80 for all the medications will be considered adherent. | 12 months | |
Secondary | Medication persistence | Persistence will be defined as the time of continuous utilization of the correspondent medication from the start of follow-up until its discontinuation (when the patient stops picking up the medication after a 60-days grace period, once the period with available medication from the previous dispensation is finished). | 12 months | |
Secondary | Therapeutic inertia | Defined as the quotient resulting of dividing the number of patients whose pharmacological treatment has not been modified, by the number of patients with SBP and/or DBP measured in the physician's practice, with values above the recommendations of the European Society of Hypertension and European Society of Cardiology. This measurements will be performed at 6, 12 and 24 months. | 6,12,24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |